Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to investigate the long-term safety and efficacy of BI 10773
given for 52 weeks as add-on therapy to one oral antidiabetic drug in patients with type 2
diabetes mellitus with insufficient glycaemic control.